NPPSMM（R&I）-BBUnewassets-上海

This role needs to take lead in one tumor area including all assets in this disease area. In addition, this role also needs to be responsible for one pan-cancer molecule across DAs to have overall compound strategy, shapes Target Product Profiles (TPPs), defines segmentation and positioning, co-develop access strategy in China, informs evidence generation, and leads cross-functional alignment, such as global strategy, forecasting team, China R&D, China medical, market access and commercial team, etc. Leading strategy and tactics to bridge existing AZ presence in specific oncology disease area into future new launchings launches by partnering with cross function team to secure non-regrettable new launches & LCM. **_ROLE & RESPONSIBILITIES_** * **Asset Strategy & TPP Ownership**: Co-lead Target Product Profile creation and iteration; define must-have clinical attributes, label aspirations, and commercial positioning. * **Insight Generation** : Commission and synthesize primary research with oncologists, pathologists, diagnosis partners, payers, and patients; integrate secondary data, RWE, and competitive intelligence into actionable strategic choices. Gather insights from field engagement with KEEs. * **Evidence Strategy Partnership** : Inform clinical, medical, and China specific evidence plans (comparators, subgroup analyses, PROs, economic models) to enable guideline inclusion, inform clinical practice guidance, and payer adoption. * **Access & Pricing Readiness**: Shape early value story, budget impact and cost-offset hypotheses, and payer evidence needs; develop pre-NDA value communication and pricing scenarios with Market Access. * **Go-to-Market Foundations** : Define early brand architecture, naming considerations, brand short-long strategy, business model and omnichannel readiness requirements; plan pre-launch disease education and KOL/advocacy engagement handoffs with medical team together. * **Analytics & Forecasting**: Lead epidemiological sizing, uptake c